Fig. 6: The glucocorticoids budesonide, mometasone and halcinonide differentiate AML samples with limited toxicity to HSPCs.
From: Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia
a Viability of bulk, CD15+ (mature blast) and CD34+ CD38− AML 8227 cells treated with budesonide, mometasone and halcinonide at indicated concentrations for 6 days. Data are representative of at least three independent experiments performed in triplicate and represents the mean ± s.d. b Colony formation of AML 8227 treated with 1 nM of mometasone for 4 days. Data are representative of two independent experiments performed in duplicate and represents mean ± s.d. c, d Viability of c bulk, CD14+ (mature blast) and CD14– CD34+ AML 9642 cells and d bulk, CD34– and CD34+ AML 9706 cells treated with indicated concentrations of mometasone for 4 days. Data represent mean ± s.d; experiment performed in triplicate. e Viability of CD34+ and CD15+ mature cord blood cells, as well as CD34+ and CD15+ AML 8227 cells treated with budesonide, mometasone and halcinonide at indicated concentrations for 4 days. Data are representative of two independent experiments performed in triplicate and represents the mean ± s.d.; **p ≤ 0.01, ***p ≤ 0.001
